|
15 December 1999
ASTRAZENECA SUBMITS FIRST REGULATORY APPLICATION FOR ITS NEW ASTHMA MEDICATION SYMBICORT® VIA EUROPEAN MUTUAL RECOGNITION
|
AstraZeneca today announced that the regulatory application for Symbicort®, budesonide and formoterol in a single inhaler (Turbuhaler®) for maintenance therapy in asthma, has been submitted to the authorities in Sweden as the first step in the European Union's mutual recognition procedure. Applications for the new product will follow in early 2000 in further countries.
|
 |
13 December 1999
ZENECA AGROCHEMICALS AND CAMBRIDGE DISCOVERY CHEMISTRY ANNOUNCE COLLABORATION
|
Cambridge Discovery Chemistry, formerly Cambridge Combinatorial, a wholly owned subsidiary of Oxford Molecular Group plc, and Zeneca Agrochemicals, the crop protection and plant science business of AstraZeneca, today (13th December) announced a major chemistry R&D collaboration.
|
|
6 December 1999
ASTRAZENECA PROGRESSES KEY PRODUCTS AND AIMS TO DOUBLE PRODUCT PORTFOLIO VALUE EVERY FIVE YEARS
|
HIGHLIGHTS
|
|
6 December 1999
APPENDIX: ASTRAZENECA R&D PIPELINE
|
Download R&D Pipeline (96k Acrobat file .pdf)
|
|
6 December 1999
HIGHLIGHTS: ASTRAZENECA's FIRST PHARMACEUTICALS R&D PRESENTATION
|
Download presentation (142k Acrobat file .pdf)
|
|
17 November 1999
ASTRAZENECA ENTITLED TO INTERLOCUTORY* INJUNCTION TO PREVENT MARKETING OF A GENERIC VERSION OF OMEPRAZOLE IN ISRAEL
|
AstraZeneca today announced that the Tel Aviv District Court has held that AstraZeneca is entitled to an interlocutory injunction in Israel based on the formulation patent, to prevent Dexcel Ltd. from marketing a generic omeprazole product.
|
|
16 November 1999
ZENECA AGROCHEMICALS ANNOUNCES INVESTMENT IN MESOTRIONE CORN HERBICIDE
|
Zeneca Agrochemicals today (16 November) announced its decision to invest $47 million in the formulation and manufacture of the new corn herbicide active ingredient mesotrione, to be produced at Zeneca's manufacturing facility at Cold Creek, Alabama, USA.
|
|
12 November 1999
ASTRAZENECA - INTERLOCUTORY INJUNCTION TO PREVENT MARKETING OF A GENERIC OMEPRAZOLE PRODUCT IN GERMANY DENIED
|
AstraZeneca today announced that its request for an interlocutory injunction in Germany to prevent Azupharma GmbH from marketing a generic omeprazole version has been denied by the Appeal Court in Frankfurt. Omeprazole is the substance used in Losec®.
|
|
28 October 1999
ASTRAZENECA NINE MONTHS RESULTS, 1999
|
Commentary (51k PDF file .pdf)Figures (82k PDF file .pdf)
|
|
27 October 1999
ASTRAZENECA DIVESTS TWO CARDIOVASCULAR MEDICINES IN SCANDINAVIAN AND EUROPEAN MARKETS TO COMPLY WITH EC MERGER CONDITIONS
|
AstraZeneca today announced the partial divestment of two cardiovascular medicines, in Scandinavian and European markets, to comply with European Commission merger conditions set in approving the merger of Astra, of Sweden, and Zeneca, of the UK, earlier this year.
|
|
21 October 1999
ASTRAZENECA SUBMITS FIRST REGULATORY APPLICATION FOR ITS NEW PPI VIA EUROPEAN MUTUAL RECOGNITION
|
AstraZeneca today announced that a regulatory application for H199/18, a new proton pump inhibitor (PPI), has been submitted to authorities in Sweden, acting as rapporteur country in the European Union's mutual recognition procedure. The new pharmaceutical contains the active substance esomeprazole.
|
|
18 October 1999
ASTRAZENECA's OMEPRAZOLE FORMULATION PATENTS
|
AstraZeneca today announced that the Tel Aviv District Court has upheld the formulation patents for omeprazole. This follows an appeal by AstraZeneca and the Israeli company Unipharm. The District Court found that the inventions subject to the patents constituted a significant advance over prior art and that they were not obvious. Omeprazole is the substance used in Losec®.
|
|
4 October 1999
ASTRAZENECA EXPANDS ACCESS TO INCYTE DATABASES AND BECOMES THE FIRST SUBSCRIBER TO INCYTE's LIFEEXPRESS RNA AND PROTEIN EXPRESSION DATABASE PROGRAM
|
Zeneca and Incyte Pharmaceuticals, Inc. of Palo Alto, California announced today that AstraZeneca has expanded its access to Incyte's databases and will become the first subscriber to Incyte's LifeExpress™ expression database program.
|
|
20 September 1999
ACCOLATE APPROVED BY FDA FOR CHILDREN WITH ASTHMA SEVEN YEARS OF AGE AND OLDER
|
A new paediatric formulation of the popular asthma medication, 'Accolate' has received approval from the U.S. Food and Drug Administration (FDA) for use in patients as young as seven years of age. The product will be available in a 10-milligram, non-flavored mini-tablet specifically designed for children. Recommended dosing is one 10-mg mini-tablet twice daily, even during symptom free periods.
|
|
13 September 1999
NEW TABLET PRODUCTION FACILITY IN GERMANY TO ENSURE FUTURE PRODUCT GROWTH
|
AstraZeneca announced today a $35 million investment in a new tablet production facility at its Plankstadt site in Germany. This plant, scheduled to start operating in 2002, will initially manufacture 'Casodex', a treatment for prostate cancer which is now the number one selling anti-androgen worldwide, and 'Zomig', a new treatment for migraine headache with or without aura, which is now launched in over 45 countries worldwide. The design of the new facility incorporates an enhanced capability for process containment making it suitable for the manufacture of complex medicines.
|
|
9 September 1999
ASTRAZENECA TO APPEAL DENIAL OF OMEPRAZOLE INTERLOCUTORY INJUNCTIONS IN GERMANY
|
AstraZeneca today announced it will appeal against a decision, not yet received in written form, by the District Court in Munich not to grant AstraZeneca's request for preliminary injunctions to prevent CT-Arzneimittel GmbH and Stadapharm GmbH to continue to sell generic omeprazole products in Germany. The decision was based on procedural grounds. The reasons given by the Court were that AstraZeneca had not filed the requests for preliminary injunctions soon enough after these generic products were put on the German market. Omeprazole is the substance used in Losec.
|
|
2 September 1999
ASTRAZENECA LAUNCHES NEW TREATMENT FOR MIGRAINE, 'Zomig', IN CHINA
|
AstraZeneca has taken an important step in developing further its business in China by launching 'Zomig', a new oral treatment for acute migraine.
|
|
23 August 1999
ASTRAZENECA GRANTED COORDINATION OF PRILOSEC® US PATENT CASES
|
AstraZeneca today announced that the Judicial Panel on Multidistrict Litigation has ordered that all pending patent infringement cases in the United States relating to omeprazole should be coordinated for pretrial proceedings in the District Court of Southern District of New York.
|
|
19 August 1999
ASTRAZENECA - INTERLOCUTORY INJUNCTION IN GERMANY TO PREVENT MARKETING OF A GENERIC OMEPRAZOLE PRODUCT UPHELD
|
AstraZeneca today announced that an Appeal Court has upheld a previously granted interlocutory injunction in Germany based on AstraZeneca's formulation patents. The injunction prevents Ratiopharm GmbH and Merckle GmbH from marketing a generic omeprazole product. Omeprazole is the substance used in Losec®.
|
|
15 August 1999
STUDY OFFERS NEW APPROACH FOR INFANTS AND YOUNG CHILDREN WITH ASTHMA
|
Once-daily use of nebulized budesonide improves asthma control in newly published pediatric study
|
|
15 August 1999
ARIMIDEX CHALLENGES TAMOXIFEN AS GOLD STANDARD TREATMENT IN WOMEN WITH ADVANCED POST-MENOPAUSAL BREAST CANCER
|
For the last 25 years the 'gold standard' treatment for women with breast cancer has been tamoxifen. New data presented today at the 10th European Cancer Conference in Vienna, Austria, challenges this dominant position. 'Arimidex', a selective non-steroidal aromatase inhibitor, has been shown to be at least as effective and well-tolerated as tamoxifen and, in one of the two international studies reported, the data indicate that 'Arimidex' is more effective.
|
|
3 August 1999
ASTRAZENECA 1999 HALF YEAR RESULTS, 3 August 1999
|
Commentary (32k Acrobat file .pdf)
|
|
8 July 1999
ASTRAZENECA WINS INTERLOCUTORY* INJUNCTION IN GERMANY TO PREVENT MARKETING OF A GENERIC VERSION OF OMEPRAZOLE
|
AstraZeneca today announced that it has been granted an interlocutory injunction in Germany based on the formulation patents to prevent Ratiopharm GmbH and Merckle GmbH from marketing a generic omeprazole product. Omeprazole is the substance used in Losec®.
|
|
30 June 1999
ASTRAZENECA COMPLETES SALE OF ZENECA SPECIALTIES
|
AstraZeneca today completed the previously announced sale of its Zeneca Specialties business for a cash amount of $2.1 billion (£1.3) in a buyout jointly financed by Cinven and Investcorp.
|
|
22 June 1999
ASTRAZENECA LAUNCHES CASODEX 150mg
|
AstraZeneca today announced the first European product launch for the new company. 'Casodex' 150 mg, a single daily tablet for the treatment of prostate cancer, is now available in the UK, the first market world-wide in which this new presentation has been introduced. It is indicated for the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable. Further launches are anticipated during 1999.
|
|
16 June 1999
GENERIC CHALLENGE TO LOSEC WITHDRAWN IN CANADA
|
The patent protection for omeprazole, the active substance in Losec, expires in Canada in July 1999. However, due to national patent legislation, in Canada the opportunity for generic competition to Losec has existed since 1996 through compulsory licensing under AstraZeneca's substance patent. AstraZeneca has several other patents approved in Canada, including a formulation patent.
|
|
16 June 1999
NEW £31 MILLION PLANT OPENING UNDERLINES SUCCESS OF ANTI-CANCER DRUG, "ZOLADEX"
|
Sir David Barnes, Deputy Chairman of AstraZeneca, today opened a new £31 million manufacturing plant for the anti-cancer drug 'Zoladex', at AstraZeneca's Macclesfield site.
|
|
16 June 1999
ASTRAZENECA AGREES TO VOTE ITS SUGEN SHARES IN SUPPORT OF PHARMACIA & UPJOHN MERGER PROPOSAL
|
AstraZeneca PLC today announced it had agreed to vote the Group's approximately 20 per cent shareholding in SUGEN, Inc., a Californian-based biotechnology company, in favour of the recently announced Pharmacia & Upjohn (P&U) and SUGEN merger proposal.
|
|
16 June 1999
CORRECTION TO EARLIER PRESS RELEASE: ASTRAZENECA TO VOTE ITS SUGEN SHARES IN SUPPORT OF PHARMACIA & UPJOHN MERGER PROPOSAL
|
Please see correction to share price in 2nd paragraph.
|
|
16 June 1999
ASTRAZENECA's CARDIOVASCULAR FRANCHISE FURTHER COMPLEMENTED BY MARKETING DEAL WITH KNOLL
|
AstraZeneca PLC today signed an agreement with Knoll AG - the pharmaceuticals arm of BASF Pharma - for the marketing of Reductil (sibutramine), an obesity management treatment, in Europe and other territories.
|
|
28 May 1999
CLOSE OF ASTRAZENECA MERGER OFFERS - ACCEPTANCES RECEIVED FROM SHAREHOLDERS REPRESENTING OVER 99.6 PER CENT OF THE SHARES IN ASTRA
|
AstraZeneca announces that by 21st May 1999, the closing date of the Merger Offers, it has received acceptances from Astra shareholders representing in total 99.6 per cent of Astra's shares and 99.7 per cent of the voting rights attaching to Astra's shares.
|
|
21 May 1999
ASTRAZENECA 1999 AGM TRADING STATEMENT
|
AstraZeneca: off to a firm start
|
|
19 May 1999
SPEECH BY TOM MCKILLOP AT ASTRAZENECA INFORMATION MEETING IN STOCKHOLM
|
Over 6,400 shareholders attended the information meeting arranged by AstraZeneca in the sports arena Globen in Stockholm on 19 May. Below you find the speech by Tom McKillop, Chief Executive of AstraZeneca, at the meeting. Attached are also his overhead slides (Acrobat file, 24 kb).
|
|
12 May 1999
ASTRAZENECA SELLS SPECIALTY CHEMICALS BUSINESS
|
AstraZeneca today announced it has agreed to sell Zeneca Specialties for a cash amount of $2.1 billion (£1.3 bn) in a buyout jointly financed by Cinven and Investcorp.
|
|
12 May 1999
ASTRAZENECA INTENDS TO APPEAL FOLLOWING REVIEW OF PATENT RULING IN AUSTRALIA
|
AstraZeneca intends to appeal a patent ruling pertaining to omeprazole (Losec®) handed down today by The Federal Court of Australia in Sydney in a dispute with the generic company Alphapharm Pty Ltd. The court clearly established, that under Australian patent law, the formulation used by Alphapharm in its generic omeprazole version infringed AstraZeneca's patented formulation technology. However, the court declared, that under Australian patent law, AstraZeneca's formulation patent was invalid.
|
|
5 May 1999
ASTRA FILES SUIT AGAINST GERMAN GENERIC COMPANY
|
Astra has filed suit in Germany against the German generic company Azupharma. The company recently launched a generic capsule version of omeprazole in Germany. Omeprazole is the substance used in Losec®.
|
|
30 April 1999
MERGER OFFERS ACCEPTANCES - OVER 99 PER CENT
|
AstraZeneca announces that it has now received in total acceptances of the Merger Offers from Astra shareholders representing 99.4 per cent of Astra's shares and 99.5 per cent of the voting rights attaching to Astra's shares.
|
|
22 April 1999
SALES OF PRILOSEC® (LOSEC®) IN THE U.S. UP 23 PERCENT DURING FIRST QUARTER OF 1999
|
Total sales of Prilosec (Losec) in the U.S. during the period January - March 1999 amounted to USD 895 m. (1998: 730 m.), an increase of 23 percent. Growth in total prescriptions February year-to-date was approximately 20 percent.
|
|
21 April 1999
CHAIRMAN OF ASTRAZENECA HAS BOUGHT ASTRAZENECA-SHARES
|
On 20 April 1999, Dr Percy Barnevik, Chairman of AstraZeneca, bought 100.000 AstraZeneca-shares at a price of SEK 342.50 per share.
|
|
19 April 1999
COMPULSORY ACQUISITION OF ASTRA AB SHARES
|
AstraZeneca PLC announces that the compulsory acquisition procedure has been initiated through its wholly owned subsidiary Zeneca Holding AB to acquire for cash those Astra shares, including shares underlying Astra ADSs, not tendered under the Merger Offers. Zeneca Holding AB owns, including subsidiary holdings, 96.2 percent of the total Astra shares representing 96.4 percent of the total voting rights attaching to Astra shares.
|
|
12 April 1999
DELISTING OF ASTRA AB
|
AstraZeneca PLC announces that Astra AB intends to apply for delisting of Astra A and B shares on the Stockholm and London Stock Exchanges with effect from Monday 26 April 1999. The last day for trading in the Astra shares on the Stockholm and London Stock Exchanges is expected to be Friday 23 April, 1999. Trading in the Astra A ADSs on the New York Stock Exchange is expected to be suspended from and including 23 April 1999, with such ADSs being delisted approximately 20 days thereafter. Trading in the Astra B ADSs was suspended on 6 April 1999 and an application will be made shortly to delist such Astra B ADSs.
|
|
6 April 1999
MERGER OFFERS DECLARED UNCONDITIONAL
|
Astra and Zeneca announce that all the conditions to the Merger Offers made by Zeneca for the issued share capital of Astra have been satisfied and that the Merger Offers are unconditional. The Merger has now been completed.
|
|
25 March 1999
FTC APPROVE ASTRAZENECA MERGER
|
Zeneca Group PLC and Astra AB announce that very significant progress has been made with regard to the US competition approval process, which is the only remaining regulatory consent required to effect the proposed Merger between the two companies. In particular, agreement has now been reached with the Staff of the Bureau of Competition of the Federal Trade Commission (FTC) on the terms of a Consent Decree which relates to a narrow product area. The Consent Decree and related agreements are subject to the approval of the FTC Commissioners who are reviewing the matter.
|
|
25 March 1999
ASTRAZENECA MERGER - CLOSING TIMETABLE AND REVISED DIVIDEND PAYMENT DATES
|
Astra AB and Zeneca Group PLC announce that, as a result of the US anti-trust approval announced earlier today, they are able to provide further details of certain aspects of the closing timetable of the proposed merger. US anti-trust approval fulfils the only remaining regulatory consent required to effect the proposed merger.
|
|
18 March 1999
ZENECA GROUP PLC/ASTRA AB MERGER AGREEMENT REACHED WITH FTC STAFF AND INITIAL OFFER PERIOD EXTENDED
|
Not for Release, Publication or Distribution, in whole or in part, in or into Canada, Australia or Japan Zeneca Group PLC and Astra AB announce that very significant progress has been made with regard to the US competition approval process, which is the only remaining regulatory consent required to effect the proposed Merger between the two companies. In particular, agreement has now been reached with the Staff of the Bureau of Competition of the Federal Trade Commission (FTC) on the terms of a Consent Decree which relates to a narrow product area. The Consent Decree and related agreements are subject to the approval of the FTC Commissioners who are reviewing the matter.
|
|
1 March 1999
EU APPROVES OF ASTRAZENECA MERGER
|
Zeneca Group PLC and Astra AB today announce that the Commission of the European Union has approved the proposed merger of Astra and Zeneca Group PLC.
|
|
18 February 1999
ZENECA GROUP PLC: RESULT OF VOTES AT EXTRAORDINARY GENERAL MEETING
|
Zeneca Group PLC announces that its shareholders have today approved all of the ordinary and special resolutions set out in the notice of the EGM contained in the Zeneca Circular dated 21st January 1999.
|
|
12 February 1999
ASTRAZENECA MERGER - COMPETITION AUTHORITY APPROVAL PROGRESS
|
Astra AB announce that Astra and Zeneca confirm that the period for the European Commission's Phase I review of the proposed merger has been extended to 1st March 1999. This is to enable the parties and the Commission to discuss certain minor aspects of the merger further.
|
|
21 January 1999
ZENECA ANNOUNCES PUBLICATION OF ASTRAZENECA MERGER DOCUMENTATION, YEAR END TRADING UPDATE AND NINE MONTHS INTERIM RESULTS
|
Not for Release, Publication or Distribution, in whole or in part, in or into Canada, Australia or JapanThe Board of Zeneca Group PLC announces that the formal merger documents in connection with its proposed merger of equals with Astra AB to form AstraZeneca will be published today.
|
|
21 January 1999
FURTHER INFORMATION REGARDING THE MERGER BETWEEN ASTRA AND ZENECA
|
The stock exchanges in Stockholm, London and New York have now approved the documentation regarding the merger between Astra and the British bioscience company Zeneca. The international prospectus will be made available at Astra AB, PR & Information, Södertälje, and at Enskilda Securities, Nybrokajen 5, Stockholm. In this connection, Astra will start distributing the prospectus.
|
|
18 January 1999
COMPETITION AUTHORITIES RECEIVE ASTRAZENECA MERGER FILINGS
|
Filings for competition law approval of the AstraZeneca merger have been made to the European Commission and the Federal Trade Commission in the U.S., it was announced today. Both regulatory bodies received the filing last Friday (January 15). They will consider the proposed merger of equals between Zeneca, a UK-based company, and Astra, of Sweden, announced last month.
|
|